CureVac share undecided before the opening hours: sales jump in third quarter – loss widened

The biotech company CureVac significantly increased its losses in the third quarter with a sharp rise in sales.

The company announced on Thursday evening in Tübingen that the revenue increased by 463 percent to 29.3 million euros compared to the same period last year. The increase in sales in the first nine months is still 44 percent. The increase was mainly due to higher sales from the cooperation with the British pharmaceutical company GlaxoSmithKline, it was said to justify.

However, the result minus also grew significantly in the past quarter. The operating loss increased from 36.7 million euros to 143.1 million euros. The main reason was higher research and development costs for CVnCoV, the first-generation COVID-19 vaccine candidate.

The NASDAQ-listed CureVac share is now 0.10 percent lower at 41.04 US dollars in pre-market trading.



Leave A Comment